Try
BeOne Medicines Ltd.
ONCUnited States
50 filed reports · 649 financial concepts · 2 earnings calls · 7 media appearances
Filed reports
50 reports · Jun 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 32 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 31 | 5,977 | Jun 2016 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 10 | 5,448 | Dec 2016 to Dec 2025 |
| Current · 8-KSEC EDGAR | 7 | 30 | Sep 2021 to Jun 2026 |
| Annual · 10-K/ASEC EDGAR | 2 | 2 | Dec 2023 to Dec 2024 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 5, 2026 | 8 | Open |
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 5, 2026 | 471 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 6, 2026 | 2 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 6, 2026 | 259 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 26, 2026 | 1,023 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 26, 2026 | 4 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Nov 6, 2025 | 4 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 6, 2025 | 308 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 6, 2025 | 194 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | May 7, 2025 | 4 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 7, 2025 | 195 | Open |
| FY2024 | 10-K/A | Dec 31, 2024 | Feb 28, 2025 | 1 | Open |
Financial data
649 concepts · 11,457 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial619 concepts · 10,551 facts · Dec 2014 to Jul 2026
- Long term debt noncurrent69 · Dec 2016 to Jun 2026
- Long term debt current68 · Sep 2017 to Jun 2026
- Cash and cash equivalents at carrying value58 · Dec 2014 to Jun 2026
- Net income loss58 · Dec 2014 to Jun 2026
- Operating income loss58 · Dec 2014 to Jun 2026
- Revenue58 · Dec 2014 to Jun 2026
- Allocated share based compensation expense57 · Dec 2014 to Jun 2026
- Costs and expenses57 · Dec 2014 to Jun 2026
- Depreciation57 · Dec 2014 to Jun 2026
- Income tax expense benefit57 · Dec 2014 to Jun 2026
- Research and development expense57 · Dec 2014 to Jun 2026
- Capital expenditures incurred but not yet paid56 · Dec 2014 to Jun 2026
- Increase decrease in accounts payable56 · Dec 2014 to Jun 2026
- Increase decrease in other accounts payable and accrued liabilities56 · Dec 2014 to Jun 2026
- Payments to acquire property plant and equipment56 · Dec 2014 to Jun 2026
- Share based compensation56 · Dec 2014 to Jun 2026
- Stockholders equity (US GAAP)55 · Dec 2014 to Jun 2026
- Comprehensive income net of tax54 · Dec 2014 to Jun 2026
- Other nonoperating income expense54 · Dec 2014 to Jun 2026
- Accounts payable current53 · Dec 2015 to Jun 2026
- Accumulated depreciation depletion and amortization property plant and equipment53 · Dec 2015 to Jun 2026
- Accumulated other comprehensive income loss net of tax53 · Dec 2015 to Jun 2026
- Additional paid in capital53 · Dec 2015 to Jun 2026
- Assets53 · Dec 2015 to Jun 2026
Product10 concepts · 603 facts · Dec 2016 to Jun 2026
- Revenue454 · Dec 2016 to Jun 2026
- Product64 · Dec 2016 to Jun 2026
- Revenue (excluding assessed tax)34 · Jun 2019 to Mar 2026
- Cost of goods and services sold (US GAAP)19 · Dec 2021 to Jun 2026
- Product revenue, net10 · Dec 2022 to Dec 2025
- Rebates, Returns and Other Deductions9 · Dec 2023 to Dec 2025
- Revenue (including assessed tax)8 · Mar 2017 to Dec 2022
- Contract with customer liability revenue recognized2 · Sep 2018 to Mar 2019
- Restructuring reserve accelerated depreciation2 · Sep 2024
- Deferred revenue revenue recognized11 · Jun 2018
Geography15 concepts · 273 facts · Dec 2014 to Jun 2026
- Revenue175 · Dec 2015 to Jun 2026
- Income loss from continuing operations before income taxes foreign24 · Dec 2015 to Dec 2024
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest12 · Dec 2014 to Dec 2016
- Income loss from continuing operations before income taxes minority interest and income loss from equity method investments10 · Dec 2015 to Dec 2018
- Current income tax expense benefit9 · Dec 2022 to Dec 2024
- Deferred income tax expense benefit9 · Dec 2022 to Dec 2024
- Income loss from continuing operations before income taxes domestic7 · Dec 2018 to Dec 2024
- Income tax expense benefit6 · Dec 2015 to Dec 2018
- Cash and Equivalents5 · Dec 2023 to Jun 2025
- Revenue (including assessed tax)4 · Dec 2021 to Sep 2022
- BeiGene USA, Inc.3 · Dec 2017
- PRC3 · Dec 2016 to Dec 2018
- Research and development revenue3 · Dec 2014 to Dec 2016
- Revenue (excluding assessed tax)2 · Dec 2021
- Capital Expenditures1 · Mar 2024
Guidance5 concepts · 30 facts · Nov 2021 to Aug 2026
- Revenue Guidance12 · Nov 2021 to Aug 2026
- Gross Margin Guidance8 · Feb 2025 to Aug 2026
- Operating Income Guidance6 · Feb 2026 to Aug 2026
- Net Income Guidance2 · Nov 2021
- Operating Income Guidance (Adjusted (non-GAAP))2 · Aug 2026
Segments
876 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis30 members · 540 facts
- Product196 · Dec 2017 to Jun 2026
- Collaboration113 · Dec 2017 to Dec 2025
- Collaboration Research And Development Service30 · Dec 2017 to Sep 2023
- Collaboration Other26 · Dec 2017 to Sep 2023
- Other Revenue26 · Sep 2024 to Jun 2026
- Collaboration Reimbursement Of Research And Development Costs17 · Dec 2017 to Dec 2021
- License16 · Dec 2019 to Dec 2022
- Right To Access Intellectual Property Revenue15 · Dec 2019 to Sep 2023
- Other14 · Dec 2023 to Jun 2026
- Rebates Returns And Other Deductions14 · Dec 2023 to Jun 2026
- Collaboration other12 · Jun 2019 to Mar 2026
- Contra Accounts Receivable Accruals8 · Mar 2024 to Jun 2026
- Right to access intellectual property revenue7 · Dec 2022 to Sep 2024
- Tislelizumab7 · Mar 2022 to Sep 2024
- Contra AR Accruals6 · Dec 2023 to Dec 2025
- Collaboration5 · Dec 2021 to Mar 2025
- Product4 · Mar 2021 to Mar 2023
- Collaboration research and development service milestone payment2 · Jun 2024 to Sep 2024
- Material rights revenue2 · Sep 2023 to Sep 2024
- BLINCYTO2 · Jun 2025 to Jun 2026
- BRUKINSA2 · Jun 2025 to Jun 2026
- Collaboration Research And Development Service Milestone Payment2 · Jun 2018 to Sep 2018
- KYPROLIS2 · Jun 2025 to Jun 2026
- License Revenue2 · Dec 2017 to Dec 2019
- Material Rights Revenue2 · Sep 2022 to Sep 2023
- POBEVCY2 · Jun 2025 to Jun 2026
- TEVIMBRA2 · Jun 2025 to Jun 2026
- XGEVA2 · Jun 2025 to Jun 2026
- Collaboration research and development service1 · Dec 2023
- Tevimbra1 · Sep 2024
Statement geographicalsrt:StatementGeographicalAxis8 members · 198 facts
- US57 · Dec 2017 to Jun 2026
- CN56 · Dec 2017 to Jun 2026
- All Other Countries Except China And United States Of America54 · Dec 2017 to Jun 2026
- Europe21 · Dec 2021 to Jun 2026
- Cn7 · Dec 2021 to Jun 2025
- All other countries except china and united states of america1 · Dec 2021
- Shanghai china1 · Mar 2024
- Us1 · Sep 2022
Statement geographicalus-gaap:StatementGeographicalAxis13 members · 75 facts
- CN18 · Dec 2014 to Dec 2018
- All Other Countries Except China And United States Of America14 · Dec 2015 to Dec 2018
- US13 · Dec 2015 to Dec 2018
- AU11 · Dec 2014 to Dec 2018
- CH4 · Dec 2017 to Dec 2018
- HK4 · Dec 2015 to Dec 2018
- All Other Countries Except Cayman Islands Peoples Republic Of China And Australia3 · Dec 2014 to Dec 2016
- KY3 · Dec 2014 to Dec 2016
- All other countries except china united states of america and switzerland1 · Dec 2021
- CA1 · Dec 2017
- Cn1 · Dec 2021
- MA1 · Dec 2017
- NJ1 · Dec 2017
Product or serviceus-gaap:ProductOrServiceAxis9 members · 63 facts
- Product19 · Dec 2016 to Dec 2018
- Collaboration10 · Dec 2016 to Dec 2018
- Collaboration Reimbursement Of Research And Development Costs9 · Dec 2016 to Dec 2018
- Collaboration Research And Development Service9 · Dec 2016 to Dec 2018
- Product6 · Mar 2021 to Sep 2022
- License Revenue5 · Dec 2016 to Dec 2018
- Collaboration2 · Mar 2017 to Dec 2019
- Collaboration Research And Development Service Milestone Payment2 · Jun 2018 to Sep 2018
- Collaboration research and development service1 · Dec 2022
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary131 claims from 10 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary154 claims from 9 reports · Dec 2023 to Jun 2026
- Risk-factor changes32 claims from 1 reports · Dec 2025
- Risk factors169 risks from 2 annual reports · 2024 to 2025
Earnings calls
2 calls · May 2026 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 5, 2026
- FY2026 Q1May 6, 2026
Executive media
7 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- Other appearances3 · Oct 2022 to Sep 2024
- Conference talks2 · Nov 2020
- Podcasts2 · Jul 2025
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.